Viewing data from:

MYQORZO

NDA

AFICAMTEN | N219083 | CYTOKINETICS INC

4 strengths2 unique patents1 unique exclusivity

Patent Timeline

2 unique patents, 1 exclusivity by expiration date

Active (2)TodayExclusivity

2026

2027

2028

2029

2030

2031

2032

2033

2034

2035

2036

2037

2038

2039

2040

2041

2042

2043

Today

10836755

Jan. 18, 2039

12370179

Jul. 15, 2042

NCE

Dec. 19, 2030

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

1 trial from ClinicalTrials.gov, 1 active

Trial	Phase	Status	Sponsor	Enrollment	Dates
A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy NCT07023341	Phase 3	Active	Bayer	36	2025-06-30 → 2028-04-28

Source: ClinicalTrials.gov. Trials matched by ingredient name.

Approval Letters

2 letters from Drugs@FDA

Date	Submission	Document
Feb 6, 2026	SUPPL -1	View Letter (PDF)
Dec 23, 2025	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (4)

Sort:

#001 — 5MG

RLD

2 patents1 exclusivity▴

TABLET;ORAL | Approved: Dec 19, 2025

Patents (2)

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
10836755	Jan 18, 2039	—	Yes	Yes		—
12370179	Jul 15, 2042	—	—	—		—

Exclusivities (1)

Code	Date	Status
NCE	Dec 19, 2030	Active

#002 — 10MG

RLD

2 patents1 exclusivity▾

TABLET;ORAL | Approved: Dec 19, 2025

#003 — 15MG

RLD

2 patents1 exclusivity▾

TABLET;ORAL | Approved: Dec 19, 2025

#004 — 20MG

RLD

2 patents1 exclusivity▾

TABLET;ORAL | Approved: Dec 19, 2025